How to Get Dayvigo (Lemborexant) in Florida

What Is Dayvigo and Why Is It Prescribed?

Dayvigo (lemborexant) is a dual orexin receptor antagonist (DORA) that the FDA approved in December 2019 for the treatment of insomnia in adults who have difficulty falling asleep or staying asleep. Unlike older sedative-hypnotics such as zolpidem, lemborexant works by blocking orexin neuropeptides that promote wakefulness rather than broadly depressing central nervous system activity 1.

How Lemborexant Differs from Older Sleep Medications

Benzodiazepine receptor agonists (the "Z-drugs") bind GABA-A receptors and carry well-documented risks of complex sleep behaviors, next-morning impairment, and dependence. Lemborexant targets the orexin-2 and orexin-1 receptors specifically, which means it reduces the wake signal without suppressing the full arousal architecture 2. In the SUNRISE-1 trial (N=1,006), lemborexant 5 mg and 10 mg significantly reduced latency to persistent sleep (LPS) compared with placebo at one month, with LPS improvements of approximately 10 to 12 minutes over placebo (P<0.01) 2.

Available Doses

Eisai manufactures Dayvigo in two tablet strengths: 5 mg and 10 mg. The recommended starting dose is 5 mg taken no more than once per night, immediately before bedtime, with at least seven hours of intended sleep remaining. Clinicians may increase to 10 mg based on clinical response and tolerability 1.

Step-by-Step: Getting a Dayvigo Prescription in Florida

The path from initial consultation to filled prescription typically involves four stages. Each has specific requirements under Florida law.

Step 1: Establish a Patient-Prescriber Relationship

Florida Statute 456.47 permits telehealth-initiated prescriber relationships for most medications, including Schedule IV controlled substances like Dayvigo. You can see a Florida-licensed physician, nurse practitioner (APRN), or physician assistant in person or through a HIPAA-compliant video platform. A phone-only visit does not meet the standard for a new controlled-substance prescription in Florida 3.

Step 2: Clinical Evaluation

Your prescriber will evaluate your sleep complaint, medical history, and current medications. Expect questions about sleep onset latency, number of awakenings, total sleep time, and daytime functioning. The American Academy of Sleep Medicine recommends cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment before pharmacotherapy, so your clinician may discuss behavioral options alongside medication 4.

No routine laboratory tests are required before starting Dayvigo. Your prescriber may order labs if there is clinical suspicion of hepatic impairment, because lemborexant is extensively metabolized by CYP3A4 and the 10 mg dose is not recommended in patients with moderate hepatic impairment 1.

Step 3: Prescription and Prior Authorization

Once your prescriber writes the prescription, the pharmacy will submit a claim to your insurer. If prior authorization (PA) is required, your prescriber's office handles the submission. The PA process for Dayvigo typically requires documentation that the patient has tried and failed at least one generic sleep agent (often zolpidem or trazodone), along with a confirmed diagnosis of insomnia disorder.

Step 4: Pick Up or Delivery

Dayvigo is stocked at major retail chains including CVS, Walgreens, and Publix pharmacies across Florida. Mail-order pharmacy is another option for 90-day fills, and 503A compounding pharmacies in Florida are licensed to prepare specialty formulations under Florida Board of Pharmacy oversight, though standard commercial tablets are almost always available.

Who Can Prescribe Dayvigo in Florida?

Florida allows several provider types to prescribe Schedule IV controlled substances. The specifics matter if you are choosing a telehealth platform or local clinic.

Physicians (MD and DO)

Any Florida-licensed medical doctor or osteopathic physician with an active DEA registration can prescribe Dayvigo without supervisory restrictions.

Advanced Practice Registered Nurses (APRNs)

Under Florida Statute 464.012, APRNs who hold a controlled-substance prescribing certification can prescribe Schedule IV drugs independently. Since January 2020, Florida APRNs no longer require a physician supervisory protocol for most prescribing, including Dayvigo 5.

Physician Assistants (PAs)

Florida PAs can prescribe Schedule IV medications under a supervisory agreement with a licensed physician. The supervising physician does not need to be on-site but must be available for consultation.

Telehealth Options for Dayvigo in Florida

Telehealth is a practical route for Florida residents in rural counties or those who prefer not to visit a sleep clinic. Florida law has been favorable to telehealth prescribing since the passage of SB 1526 in 2019, which expanded permissible telehealth modalities.

What to Look for in a Telehealth Provider

Choose a platform where the prescriber holds an active Florida medical license and a DEA registration in Florida. The visit should be conducted via live, synchronous audio-video communication. Platforms that offer asynchronous (questionnaire-only) consultations cannot initiate a controlled-substance prescription under Florida rules.

Prescription Transmission

Your telehealth prescriber will send the Dayvigo prescription electronically to a Florida pharmacy of your choice. Electronic prescribing for controlled substances (EPCS) is the standard in Florida and is required by most major pharmacy chains.

Turnaround time from completed telehealth visit to pharmacy pickup is typically 24 to 72 hours, depending on whether prior authorization is needed. If PA is required, add three to five business days for insurer review.

Insurance Coverage and Cost in Florida

The out-of-pocket cost for Dayvigo without insurance runs between $350 and $420 for a 30-day supply at most Florida retail pharmacies. Insurance coverage varies significantly by plan type.

Commercial Insurance

Most major commercial carriers in Florida (Blue Cross Blue Shield of Florida, Aetna, Cigna, UnitedHealthcare) include Dayvigo on their formularies, usually as a non-preferred brand on Tier 3 or Tier 4. PA is almost always required. Typical copays with PA approval range from $30 to $75 per month, depending on your plan's cost-sharing structure.

A 2022 analysis of commercial claims data found that approximately 68% of prior authorization requests for DORAs were approved on first submission when step therapy documentation was complete 6.

Florida Medicaid

Florida Medicaid does not cover Dayvigo for insomnia as of 2026. The drug is listed on the Florida Medicaid Preferred Drug List only for type 2 diabetes indications (where orexin modulation is not the relevant pathway), meaning insomnia patients on Medicaid will need to pursue manufacturer assistance or out-of-pocket payment.

Eisai Copay Assistance

Eisai offers a copay savings card for commercially insured patients that can reduce out-of-pocket costs to as low as $0 per fill for eligible patients. This card is not valid for patients covered by government programs (Medicare, Medicaid, Tricare, VA) 1.

Prior Authorization Requirements in Florida

Prior authorization for Dayvigo follows a fairly standardized pattern across Florida insurers. Knowing what documentation your prescriber needs to submit can speed up approval.

Typical PA Documentation

Most Florida insurers require three elements in a PA submission for Dayvigo:

1. A confirmed diagnosis of insomnia disorder (ICD-10 code G47.00 or G47.01)
2. Documentation that the patient has tried and had an inadequate response to, or has a contraindication to, at least one generic sleep medication (zolpidem, eszopiclone, or trazodone)
3. A statement from the prescriber explaining the clinical rationale for Dayvigo over available generics

Appeals Process

If the initial PA is denied, Florida law (FL Statute 627.42392) guarantees the right to an expedited appeal. Your prescriber submits a peer-to-peer review request with the insurer's medical director. In urgent situations, the insurer must respond within 72 hours. The Endocrine Society and the American Academy of Sleep Medicine have both noted the clinical importance of orexin-targeted therapies for patients who cannot tolerate GABA-ergic agents 4.

Clinical Evidence Supporting Lemborexant

The FDA approval of Dayvigo rested primarily on two Phase III trials. Prescribers and patients should understand what these trials showed.

SUNRISE-1 Trial

SUNRISE-1 was a randomized, double-blind, placebo- and active-comparator (zolpidem extended-release 6.25 mg) controlled trial in 1,006 adults aged 55 and older with insomnia disorder 2. At one month, lemborexant 5 mg and 10 mg both significantly improved objective sleep onset (LPS measured by polysomnography) compared with placebo. Lemborexant 10 mg also showed superiority to zolpidem ER on wake-after-sleep-onset (WASO) in the second half of the night, suggesting better sleep maintenance without the residual sedation profile of zolpidem 2.

SUNRISE-2 Trial

SUNRISE-2 evaluated lemborexant over six months in adults aged 18 and older (N=949) and demonstrated sustained efficacy on subjective sleep onset latency and sleep efficiency with no evidence of rebound insomnia upon discontinuation 7. The most common adverse effect was somnolence, reported in 10% of the 10 mg group versus 1% of the placebo group.

Safety Profile

The FDA label carries a class warning for complex sleep behaviors (sleep-driving, sleep-walking) shared by all prescription insomnia medications, though post-marketing data for DORAs suggest a lower incidence compared with Z-drugs. Lemborexant is classified as Schedule IV, reflecting a lower abuse potential relative to Schedule II or III agents. The drug should not be used in patients with narcolepsy 1.

Transferring a Dayvigo Prescription to Florida

Patients relocating to Florida or visiting for extended stays can transfer an existing Dayvigo prescription from another state, with some constraints.

Interstate Transfer Rules

Florida Board of Pharmacy rules allow the transfer of Schedule IV prescriptions between pharmacies, including across state lines, provided the prescription has remaining refills. The receiving Florida pharmacy will contact your out-of-state pharmacy to verify the prescription and transfer details. A prescription with zero remaining refills cannot be transferred and will require a new prescription from a Florida-licensed prescriber.

Temporary Residents and Snowbirds

If you spend winters in Florida but maintain primary care elsewhere, a Florida telehealth visit is the most efficient route to a local prescription. Your out-of-state prescriber can also call in a limited supply (up to 30 days) to a Florida pharmacy in an emergency, but this is not sustainable long-term and does not satisfy PA requirements for ongoing fills.

503A Compounding Pharmacies and Lemborexant in Florida

Florida has a well-regulated 503A compounding sector under the oversight of the Florida Board of Pharmacy. Some patients ask whether compounded lemborexant is available.

Current Status

Lemborexant is a patented compound under Eisai's exclusivity, and 503A pharmacies cannot compound a commercially available drug unless the prescriber documents a specific patient need that the commercial product does not meet (such as an allergy to an inactive ingredient or a need for an alternative dosage form). In practice, almost all Florida patients will fill Dayvigo as the commercial tablet. Compounding pharmacies in Florida are licensed to ship within the state, but federal law restricts 503A distribution across state lines to less than 5% of total prescriptions dispensed 8.

Tips for a Faster Prescription Process

Short timelines matter when you are not sleeping. These steps can cut days off the process.

Ask your prescriber to document prior medication failures in the chart note before the pharmacy submits the claim. Pre-loading this information prevents the common back-and-forth between insurer and prescriber that adds three to five days. Request that your prescriber use the insurer's electronic PA portal (CoverMyMeds or SureScripts) rather than fax, as electronic submissions process 40% faster on average 6.

If you are paying out-of-pocket, ask the pharmacy to run the Eisai copay card at the point of sale. Some pharmacies do not automatically apply manufacturer cards unless prompted.

Consider a 90-day mail-order fill once you are stable on Dayvigo. Mail-order pharmacies typically offer lower per-unit costs and eliminate monthly trips.